← Back to Pardes Biosciences Stock
Pardes Biosciences (PRDS) News
CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the “CVR”) associ.
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not mor.
LOS ANGELES, CA / ACCESSWIRE / August 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc. Under the terms of the proposed transaction, MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amou.
LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.